Literature DB >> 15040114

[Surgery of ossifying fibroma of the sinuses].

Shun-jiu Cui1, Bing Zhou, De-ming Han, Ming Liu, Hua-chao Liu, Qian Huang, Luo Zhang, Wen-tong Ge, Xiao-tian Zhao.   

Abstract

OBJECTIVE: To explore the different surgical choices for treating the ossifying fibroma of the sinuses. To summarize the management and characteristics of each surgical operation.
METHODS: A retrospective evaluation of thirty-five patients with ossifying fibroma of the sinuses from August 1994 to July 2001 was presented.
RESULTS: Among 22 patients operated by nasal endoscopic management, complete ossifying fibroma removed was achieved in 8 cases, and the majority part of tumor removed in 14 cases. Six patients were operated through a lateral rhinotomy with radical operation in 4 cases. Five ossifying fibromas were removed with a coronal incision. Two cases underwent Caldwell-Luc' surgery. The clinical symptoms, location of ossifying fibroma, and surgical procedures were analyzed. All patients outcomes were successful, no serious complication from the surgical technique occurred. Thirty-three cases were followed-up for 1 to 8 years with an average of three and half years. Fourteen patients had no recurrence, fourteen cases lived with the remains of ossifying fibroma, and five cases recurred.
CONCLUSIONS: The choice of surgical operations on ossifying fibroma of the sinuses was mainly decided by the location of ossifying fibroma, in the meanwhile, the organ function, the cosmetology, the surgical degree of difficulty, and the doctor's experience were taken into account.

Entities:  

Mesh:

Year:  2003        PMID: 15040114

Source DB:  PubMed          Journal:  Zhonghua Er Bi Yan Hou Ke Za Zhi        ISSN: 0412-3948


  1 in total

1.  Intranasal endoscopic prelacrimal recess approach to sinonasal juvenile ossifying fibroma.

Authors:  Ping Ye; Li-Qiang Zhang; Xue-Zhong Li; Xiao-Lan Cai; Xin-Liang Pan; Qian Huang; Rui-Lan Zhang; Xin Feng; Li Shi; Bing Zhou
Journal:  Chin Med J (Engl)       Date:  2015-02-05       Impact factor: 2.628

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.